Literature DB >> 31114961

YKL-40 promotes the progress of atherosclerosis independent of lipid metabolism in apolipoprotein E-/- mice fed a high-fat diet.

Lei Chen1, Jianlei Zheng2, Qi Xue3, Yan Zhao3.   

Abstract

YKL-40 is recently regarded as a pro-inflammatory cytokine involved in the pathological process of atherosclerosis and lipid metabolism. However, whether YKL-40 can directly influence the development of atherosclerosis and levels of lipid parameters is unknown. The aim of this study is to explore the effects of YKL-40 on atherosclerotic features, the levels of serum lipids, and biomarkers in apolipoprotein (E)-deficient (ApoE-/-) mice fed a high-fat diet. ApoE-/- mice were injected with a recombinant adenovirus expressing mouse YKL-40 or control adenovirus through the caudal vein. The levels of serum YKL-40, interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-alpha), matrix metalloproteinase-9 (MMP-9), and soluble vascular cell-adhesion molecule 1 (sVCAM-1) were measured by ELISA. Lipid metabolism parameters were measured using immunoturbidimetric assay. The size of plaque area in aorta was evaluated by Oil Red O and hematoxylin/eosin (HE) staining. The content of collagen fibers was stained with Masson, and the content of macrophages and smooth muscle cells (SMCs) in atherosclerotic lesions was investigated by immunohistochemistry. The serum levels of total cholesterol and triglycerides were similar between these two groups. Compared with the control, the levels of serum YKL-40, IL-6, TNF-alpha, MMP-9, plaque size, and macrophages in plaques were significantly increased in mice with adenovirus overexpressing YKL-40. However, the content of collagen fibers and SMCs was remarkably decreased in mice with adenovirus overexpressing YKL-40 than that in control. YKL-40 prompts the progress of atherosclerosis maybe involved with its role of pro-inflammation, but does not affect lipid metabolism in ApoE-/- mice fed a high-fat diet.

Entities:  

Keywords:  Atherosclerosis; Inflammation; Lipid metabolism; YKL-40

Mesh:

Substances:

Year:  2019        PMID: 31114961     DOI: 10.1007/s00380-019-01434-w

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  41 in total

1.  A YKL-40-neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers.

Authors:  Michael Faibish; Ralph Francescone; Brooke Bentley; Wei Yan; Rong Shao
Journal:  Mol Cancer Ther       Date:  2011-02-25       Impact factor: 6.261

Review 2.  Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions.

Authors:  Paolo Raggi; Jacques Genest; Jon T Giles; Katey J Rayner; Girish Dwivedi; Robert S Beanlands; Milan Gupta
Journal:  Atherosclerosis       Date:  2018-07-25       Impact factor: 5.162

3.  Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris.

Authors:  Daiju Fukuda; Kenei Shimada; Atsushi Tanaka; Takanori Kusuyama; Hajime Yamashita; Shoichi Ehara; Yasuhiro Nakamura; Takahiko Kawarabayashi; Hidetaka Iida; Minoru Yoshiyama; Junichi Yoshikawa
Journal:  Am J Cardiol       Date:  2005-11-17       Impact factor: 2.778

Review 4.  Adipose tissue, inflammation and atherosclerosis.

Authors:  Birgit Gustafson
Journal:  J Atheroscler Thromb       Date:  2010-02-03       Impact factor: 4.928

Review 5.  Update on acute coronary syndromes: the pathologists' view.

Authors:  Erling Falk; Masataka Nakano; Jacob Fog Bentzon; Aloke V Finn; Renu Virmani
Journal:  Eur Heart J       Date:  2012-12-13       Impact factor: 29.983

6.  Increased serum YKL-40 and C-reactive protein levels are associated with angiographic lesion progression in patients with coronary artery disease.

Authors:  Jian Lei Zheng; Lin Lu; Jian Hu; Rui Yan Zhang; Qi Zhang; Qiu Jin Chen; Wei Feng Shen
Journal:  Atherosclerosis       Date:  2009-12-21       Impact factor: 5.162

7.  Chitinase 3-like 1 promotes macrophage recruitment and angiogenesis in colorectal cancer.

Authors:  M Kawada; H Seno; K Kanda; Y Nakanishi; R Akitake; H Komekado; K Kawada; Y Sakai; E Mizoguchi; T Chiba
Journal:  Oncogene       Date:  2011-11-07       Impact factor: 9.867

8.  Associations of the Inflammatory Marker YKL-40 with Measures of Obesity and Dyslipidaemia in Individuals at High Risk of Type 2 Diabetes.

Authors:  Stine B Thomsen; Anette P Gjesing; Camilla N Rathcke; Claus T Ekstrøm; Hans Eiberg; Torben Hansen; Oluf Pedersen; Henrik Vestergaard
Journal:  PLoS One       Date:  2015-07-21       Impact factor: 3.240

Review 9.  Prevalence, Treatment, and Control of Hypercholesterolemia in High Cardiovascular Risk Patients: Evidences from a Systematic Literature Review in Spain.

Authors:  Alex de la Sierra; Xavier Pintó; Carlos Guijarro; José López Miranda; Daniel Callejo; Jesús Cuervo; Rudi Subirà; Marta Rubio
Journal:  Adv Ther       Date:  2015-10-26       Impact factor: 3.845

10.  Change of Inflammatory Factors in Patients with Acute Coronary Syndrome.

Authors:  Cai-Yun Ma; Zhen-Ye Xu; Shao-Ping Wang; Hong-Yu Peng; Fang Liu; Jing-Hua Liu; Feng-Xue Ren
Journal:  Chin Med J (Engl)       Date:  2018-06-20       Impact factor: 2.628

View more
  3 in total

1.  Silencing METTL3 Stabilizes Atherosclerotic Plaques by Regulating the Phenotypic Transformation of Vascular Smooth Muscle Cells via the miR-375-3p/PDK1 Axis.

Authors:  Jingquan Chen; Kun Lai; Xi Yong; Hongshun Yin; Zhilong Chen; Haifei Wang; Kai Chen; Jianghua Zheng
Journal:  Cardiovasc Drugs Ther       Date:  2022-06-15       Impact factor: 3.727

2.  Adenovirus vector-mediated YKL-40 shRNA attenuates eosinophil airway inflammation in a murine asthmatic model.

Authors:  Ling Wang; Aihua Bao; Ying Zheng; Aying Ma; Yi Wu; Huanxia Shang; Danruo Fang; Suqin Ben
Journal:  Gene Ther       Date:  2020-10-12       Impact factor: 5.250

3.  Downregulation of Interleukin-13 Receptor α2 Inhibits Angiogenic Formation Mediated by Chitinase 3-Like 1 in Late Atherosclerotic Lesions of apoE-/- Mice.

Authors:  Qi Xue; Lei Chen; Jianwu Yu; Kewang Sun; Lifang Ye; Jianlei Zheng
Journal:  Front Physiol       Date:  2021-07-19       Impact factor: 4.566

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.